Antiangiogenesis: new frontiers in therapeutic development.
LaMontagne
Kenneth R
KR
Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey, USA. klamontagne@prdus.jnj.com
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000097:blood; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000097:blood / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor